CLINICAL TRANSPLANTATION, cilt.30, sa.10, ss.1216-1221, 2016 (SCI-Expanded)
BackgroundThe aim of this study was to determine the long-term efficacy of nucleos(t)ide analog (NA) and low-dose hepatitis B immunoglobulin (HBIG) combination treatment for preventing post-transplant hepatitis B virus (HBV) recurrence.